Drug Master File (DMF) Submission Guidelines FDA
A Drug Master File (DMF) is a confidential, detailed document submitted to regulatory authorities like the US FDA to provide information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. Although DMF submission is not a regulatory requirement, it is a valuable tool for protecting the proprietary information of manufacturers while supporting regulatory approval of drug applications such as ANDAs, NDAs, or INDs.
This article provides a step-by-step guide on how to prepare and submit a Drug Master File (DMF), primarily focusing on submission to the U.S. Food and Drug Administration (FDA).
What Is a Drug Master File (DMF)?
A Drug Master File (DMF) is a confidential document submitted to the U.S. Food and Drug Administration (FDA) that provides detailed information about the manufacturing, processing, packaging, storage, and controls of drug-related components. These components can include active pharmaceutical ingredients (APIs), excipients, packaging materials, or other raw materials used in the production of human drugs. The DMF is not a mandatory requirement but serves as a valuable tool for protecting proprietary information while supporting regulatory submissions like ANDAs, NDAs, and INDs.
Why Is a Drug Master File (DMF) Submitted?
The primary reason for submitting a Drug Master File is to allow drug product applicants to reference sensitive technical information without disclosing it publicly or to third parties. For example, an API manufacturer may submit a Type II DMF and provide a Letter of Authorization (LOA) to a pharmaceutical company, enabling that company to include the API details in their drug application without accessing proprietary manufacturing data.
Submitting a Drug Master File also helps streamline regulatory review by giving the FDA direct access to validated, consistent information on a specific substance or material. It enhances compliance, facilitates faster approvals, and builds trust between manufacturers and drug product applicants while maintaining confidentiality.
Types of Drug Master File
The FDA currently accepts five types of Drug Master File:
Type I: Manufacturing Site, Facilities, Operating Procedures (No longer accepted by the US FDA)
Type II: Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product
Type III: Packaging Material
Type IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation
Type V: FDA-Accepted Reference Information (used only with FDA’s written authorization)
Step-by-Step Process for Drug Master File- DMF Submission
Step 1: Select the DMF Type and Its Regulatory Purpose
The first step in submitting a Drug Master File (DMF) is to carefully select the appropriate Drug Master File type based on the nature of the product or material being submitted and its intended regulatory purpose. The FDA currently accepts DMFs of Type II, III, IV, and V, each designed to cover specific components used in pharmaceutical products.
Understanding the regulatory purpose is equally important. A Drug Master File is not reviewed independently but is referenced in a drug application such as an ANDA, NDA, or IND. By selecting the correct DMF type and clearly defining its role in supporting a regulatory submission, you ensure that your file meets FDA expectations and serves its intended purpose effectively.
Step 2: Prepare the Drug Master File (DMF) Content According to CTD Format
The first and most critical step in preparing a Drug Master File (DMF) is to determine the correct type of DMF and clearly define its purpose. This ensures that the file meets regulatory expectations and serves the intended function in supporting a drug application (e.g., ANDA, NDA, IND).
Types of Drug Master File (DMF) Accepted by the FDA
The U.S. FDA accepts the following Drug Master File types:
1. Type II – Drug Substance, Drug Substance Intermediate, and Drug Product
Most commonly used DMF type.
Contains detailed information about:
The active pharmaceutical ingredient (API)
Drug substance intermediates
Drug products (formulation, manufacturing, controls)
Purpose: Supports ANDA/NDA submissions by allowing applicants to reference proprietary data about an API or finished drug product without disclosing trade secrets.
2. Type III – Packaging Material
Describes materials used in the packaging of drug products.
Includes:
Composition of packaging
Manufacturing process
Specifications and test methods
Toxicology or safety data
Purpose: To support the safety and compatibility of packaging components used in pharmaceuticals.
3. Type IV – Excipient, Colorant, Flavor, Essence
Details about inactive ingredients used in the formulation.
Includes:
Identity and chemical structure
Manufacturing process
Quality control parameters
Safety data
Purpose: Used when an excipient or flavoring agent is manufactured by a third party and is referenced by a drug applicant.
4. Type V – FDA-Accepted Reference Information
Contains miscellaneous or supportive information not covered in Types II–IV.
Requires prior FDA authorization before submission.
Purpose: May include summaries, safety updates, or multiple component references. Should only be submitted if specifically requested by the FDA.
Important Notes
Type I DMFs (Facilities, Manufacturing Sites, Operating Procedures) were previously used but are no longer accepted by the FDA for new submissions.
Each DMF must have a specific and well-defined purpose, typically in support of another party’s regulatory submission (e.g., ANDA, NDA).
Once the DMF type and purpose are determined, you can proceed with requesting a pre-assigned DMF number from the FDA.
Step 3: Assign a DMF Number
Before submitting a Drug Master File (DMF) to the FDA, it is mandatory to obtain a pre-assigned DMF number. This number serves as the official identifier for your DMF throughout its lifecycle and must be included in all related documents and correspondence. Without a valid DMF number, your submission will not be accepted or acknowledged by the FDA.
How to Request a Pre-Assigned DMF Number
The FDA requires all pre-assignment requests to be submitted electronically through its Electronic Submissions Gateway (ESG).
List of important documents:
1. Form FDA 3938 – Drug Master File Number Request Form
Form FDA 3938 is a required document for obtaining a pre-assigned DMF number from the U.S. FDA. It collects key administrative details such as the DMF type (II, III, IV, or V), contact information of the DMF holder, and a brief description of the file’s contents. This helps the FDA understand the purpose and scope of the submission. The completed form must be submitted in PDF format through the FDA’s Electronic Submissions Gateway (ESG).
2. Letter of Intent
The Letter of Intent is a signed document indicating your plan to submit a Drug Master File (DMF) to the FDA. It should clearly state the company name and address, specify the type of DMF (e.g., Type II for drug substance), outline the purpose of the submission, and provide the contact details of the responsible person, including name, title, phone number, and email. This letter must be submitted in PDF format along with Form FDA 3938 through the FDA’s Electronic Submissions Gateway (ESG).
3. Company Information
When requesting a DMF number, you must provide detailed company information. This includes the legal name of the company, its D-U-N-S number (if available), and the names and contact details of both a primary and secondary contact person. These individuals should be authorized to communicate with the FDA regarding the DMF and capable of responding to regulatory queries.
Accurate and up-to-date information ensures smooth correspondence and processing of your DMF number request.Once the FDA reviews and approves your request, it will issue a unique DMF number (e.g., DMF #026584) via email. This number must be clearly referenced in the cover letter, eCTD submission metadata, and Letter of Authorization (LOA). It is crucial to ensure the accuracy and consistency of this number in all future communications and updates related to your DMF.
Step 4: Compile in Electronic Format (eCTD)
The FDA requires all DMF submissions to be in eCTD (electronic Common Technical Document) format. Key requirements include:
Valid XML backbone
Hyperlinked and bookmarked PDFs
Proper granularity and sequence numbering
Compliance with FDA eCTD validation criteria
Recommended software tools: Lorenz DocuBridge, Extedo eCTDmanager, GlobalSubmit, etc.
Step 5: Submit Through ESG (Electronic Submissions Gateway)
To submit a Drug Master File (DMF), you must be registered with the FDA Electronic Submissions Gateway (ESG). Once registered:
Log in to ESG
Upload the eCTD zip file (with proper structure)
Monitor for FDA Acknowledgement (Receipt confirmation)
Step 6: Submit Letter of Authorization (LOA)
If you want to authorize a drug product applicant to reference your Drug Master File (DMF), you must provide a Letter of Authorization (LOA), which includes:
Drug Master File (DMF) number
Holder and applicant names
Specific information authorized (e.g., sections)
Signature and contact details of the Drug Master File holder
The LOA must also be submitted both to the FDA and to the drug applicant using the DMF.
Step 7: Maintain and Update the Drug Master File DMF
Once submitted, the Drug Master File should be updated regularly, especially when:
There are significant changes in manufacturing, specifications, or facilities
The FDA requests additional information or clarification
Annual reports are due (the FDA expects an Annual Report to maintain the DMF’s active status)
Important Considerations for Drug Master File Submission
Confidentiality: Drug Master File allow you to keep proprietary manufacturing details confidential while still supporting your clients’ submissions.
Drug Master File Review: The FDA does not approve or disapprove DMFs but reviews them when referenced in drug applications.
Fees: Type II DMFs used to support generic drug submissions are subject to a DMF fee as per GDUFA regulations.
Inactive Drug Master File: If a DMF is not referenced for a long period or lacks annual updates, it may be deemed inactive by the FDA.
Conclusion
Submitting a Drug Master File requires meticulous preparation, technical accuracy, and ongoing maintenance. Whether you’re a manufacturer, supplier, or API producer, understanding the DMF process is crucial for regulatory compliance and protecting intellectual property. By following the FDA guidelines and using the eCTD format, you can ensure a smooth submission and provide critical support to your business partners’ drug applications.